Concerns about patient safety, reports of increased suicidal thinking and allegations of flawed research are at the heart of a new complaint to Health Canada over the much-hyped clinical trials for the use of MDMA to treat post-traumatic stress disorder.
'We decided to figure out how to love again,' Sask. residential school survivor says of 69-year marriagePapal apology for church's role in residential schools may not be 'way forward': archbishopAs vaccination rates climb, thoughts across the North turn to reopeningNew Brunswick's little-known school for assimilating Indigenous childrenOttawa approves NHL travel exemption for Stanley Cup playoffs
0 comments:
Post a Comment